|
gptkbp:instanceOf
|
immunosuppressant
mTOR inhibitor
macrolide
|
|
gptkbp:administeredBy
|
oral route
|
|
gptkbp:affects
|
T-cell activation
B-cell differentiation
|
|
gptkbp:alsoKnownAs
|
gptkb:rapamycin
|
|
gptkbp:approvedBy
|
gptkb:FDA
1999
|
|
gptkbp:ATCCode
|
L04AA10
|
|
gptkbp:brand
|
gptkb:Rapamune
|
|
gptkbp:CASNumber
|
53123-88-9
|
|
gptkbp:category
|
immunosuppressants
antineoplastic agents
antifungal antibiotics
|
|
gptkbp:contraindication
|
hypersensitivity to sirolimus
|
|
gptkbp:discoveredBy
|
gptkb:Surendra_Nath_Sehgal
|
|
gptkbp:discoveredIn
|
gptkb:Easter_Island
1972
|
|
gptkbp:eliminationHalfLife
|
~62 hours
|
|
gptkbp:foundIn
|
Easter Island soil samples
|
|
gptkbp:hasMolecularFormula
|
C51H79NO13
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sirolimus
|
|
gptkbp:inhibitedBy
|
gptkb:mTORC1
|
|
gptkbp:interactsWith
|
gptkb:milk
gptkb:cyclosporine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits mTOR pathway
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
914.172 g/mol
|
|
gptkbp:notableFor
|
increasing longevity in animal models
|
|
gptkbp:origin
|
gptkb:Streptomyces_hygroscopicus
|
|
gptkbp:patentExpired
|
2014
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00877
5284616
|
|
gptkbp:relatedTo
|
gptkb:everolimus
gptkb:temsirolimus
gptkb:ridaforolimus
|
|
gptkbp:sideEffect
|
thrombocytopenia
hyperlipidemia
mouth ulcers
impaired wound healing
|
|
gptkbp:UNII
|
QF9D89GV90
|
|
gptkbp:usedFor
|
treatment of certain cancers
prevention of organ transplant rejection
treatment of lymphangioleiomyomatosis
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
gptkb:mTOR_pathway
gptkb:Afinitor
|
|
gptkbp:bfsLayer
|
5
|